Efficacy and safety of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: Further outcomes from the IMPROVE study

Journal of the Neurological Sciences

Volumn 312, Issue 1-2, 2012, Pages 97-101

  De Stefano, Nicola ^a   Sormani, Maria Pia ^b   Stubinski, Bettina ^c   Blevins, Gregg ^d   Drulovic, Jelena S ^e   Issard, Delphine ^c   Shotekov, Penko ^f   Gasperini, Claudio ^g  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Merck Serono GmbH   (Germany)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF BELGRADE   (Serbia)

^f Clinic of Neurology   (Bulgaria)

^g SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Efficacy; Interferon beta 1a; Magnetic resonance imaging; Randomized controlled trial; Relapsing remitting multiple sclerosis; Safety

Indexed keywords

BETA1A INTERFERON; GADOLINIUM; PLACEBO;

ARTICLE; BRAIN SCINTISCANNING; CONTROLLED STUDY; CYTOPENIA; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; SUICIDAL IDEATION; THYROID DISEASE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ALBUMINS; ANIMALS; ANTIBODIES, NEUTRALIZING; ATROPHY; CATTLE; CHEMISTRY, PHARMACEUTICAL; GADOLINIUM; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; SERUM ALBUMIN, BOVINE; TREATMENT OUTCOME;

EID: 84155167325     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2011.08.013     Document Type: Article

References (11)

1. ® New Formulation) in a phase IIIb study in patients with relapsing multiple sclerosis: 96-week results Mult Scler 15 2009 219 228
2. L. Kappos, A. Traboulsee, C. Constantinescu, J.P. Eralinna, F. Forrestal, and P. Jongen Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS Neurology 67 2006 944 953 (Pubitemid 44454583)
3. PRISMS Study Group Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis Lancet 352 1998 1498 1504
4. PRISMS Study Group University of British Columbia MS/MRI Analysis Group PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS Neurology 56 2001 1628 1636
5. SPECTRIMS Study Group Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results Neurology 56 2001 1496 1504
6. N. De Stefano, F. Curtin, B. Stubinski, G. Blevins, J. Drulovic, and S. Issard Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis Mult Scler 16 2010 888 892
7. S.M. Smith, Y. Zhang, M. Jenkinson, J. Chen, P.M. Matthews, and A. Federico Accurate, robust, and automated longitudinal and cross-sectional brain change analysis Neuroimage 17 2002 479 489
8. M.P. Sormani, L. Bonzano, L. Roccatagliata, G.R. Cutter, G.L. Mancardi, and P. Bruzzi Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach Ann Neurol 65 2009 268 275
9. G. Giovannoni, O. Barbarash, F. Casset-Semanaz, A. Jaber, J. King, and L. Metz Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis Clin Ther 29 2007 1128 1145 (Pubitemid 47208583)
10. P.S. Sorensen, F. Deisenhammer, P. Duda, R. Hohlfeld, K.M. Myhr, and J. Palace Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis Eur J Neurol 12 2005 817 827 (Pubitemid 41597593)
11. P.S. Sorensen, N. Koch-Henriksen, C. Ross, K.M. Clemmesen, and K. Bendtzen Appearance and disappearance of neutralizing antibodies during interferon-beta therapy Neurology 65 2005 33 39 (Pubitemid 40967773)